Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to accelerate patient identification and recruitment for Prothena’s ASCENT-2 clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease.
Lead Product(s): PRX012
Therapeutic Area: Neurology Product Name: PRX012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Prothena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2023